Navigation Links
Drug doesn't significantly lower risk of major heart problems in dialysis patients
Date:11/3/2012

In one of the largest and longest trials involving patients with kidney failure, a study led by an international team of researchers found that cinacalcet a drug commonly prescribed to patients with kidney failure and a disturbance of bone and mineral metabolism known as secondary hyperparathyroidism does not significantly reduce the risk of death or major cardiovascular events.

The results of the trial known as EVOLVE, which enrolled nearly 4,000 kidney patients from several continents and stretched over five years, were mixed, researchers said.

"The results of the EVOLVE trial suggest that cinacalcet favorably alters bone and mineral metabolism, and could result in improved health and longevity for patients with end-stage renal disease," said the study's lead author, Glenn Chertow, MD, professor of medicine and chief of nephrology at the Stanford University School of Medicine. "But the trial was not definitive in determining cardiovascular benefits because so many patients discontinued taking the study drug."

Researchers did say the trial results showed possible cardiovascular benefits when certain factors were taken into account, such as an imbalance in age between study participants who were treated with cinacalcet and those who received a placebo. Those who received the drug were on average a year older; age is a major risk factor for cardiovascular disease.

"The trial is not definitive in its results; however, recognizing some of the limitations such as the high dropout rate it is suggestive of a cardiovascular health benefit," said co-author Geoffrey Block, MD, medical director of Denver Nephrology.

The study will be published online Nov. 3 in the New England Journal of Medicine and will also be presented at the American Society of Nephrology annual meeting in San Diego the same day.

Patients on kidney dialysis are among the most frail and chronically ill, with high mortality and hospitaliz
'/>"/>

Contact: Tracie White
traciew@stanford.edu
650-723-7628
Stanford University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Rheumatic heart disease is significantly under-treated in Africa and India
2. Canada should significantly increase its funding of randomized clinical trials
3. Lowering the national ozone standard would significantly reduce mortality and morbidity
4. Accelerated resolution therapy significantly reduces PTSD symptoms, researchers report
5. Study: Vaccine targets malignant brain cancer antigens, significantly lengthens survival
6. Non-invasive diagnostic imaging costs to Medicare Part B down significantly since 2006
7. Marital status, race increase survival rate significantly for Stage III non-small cell lung cancer patients
8. Only children are significantly more likely to be overweight
9. Outpatient urological surgery costs significantly less when performed in physician offices & ACCs
10. Lower GI problems plague many with rheumatoid arthritis, Mayo Clinic study finds
11. Tree nut consumption associated with lower body weight and lower prevalence of health risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2015)... Indiana Fiber Network, LLC (IFN), the ... Mutual Insurance Company has selected IFN as a fiber ... at Brotherhood Mutual Insurance Company states: “IFN’s broadband fiber ... Mutual needed. We were interested in building ... us to ensure we achieved both. ” ...
(Date:4/26/2015)... India Network Foundation, a non-profit organization ... services to the Asian Indian community in the United ... more than two decades. The India News Network Digest ... around the world with the latest news items from ... Immigration Law Forum Digest, edited and contributed by Sheela ...
(Date:4/26/2015)... 2015 The grand celebration got off to ... Dettor, CCAR’s Managing Director. Deb then introduced Sandy Valentine, the ... in attendance because of his Walk for Recovery ... able to express his gratitude to the volunteers via video. ... dedication to carrying out CCAR’s mission. Volunteer Manager Conrad ...
(Date:4/25/2015)... Francisco, California (PRWEB) April 26, 2015 ... his search for original 1965 Rolling Stones Greensboro Coliseum concert ... and was part of the Stone's Second American Tour. ... by Globe Poster Company out of Baltimore, Maryland. This ... in the northeast and southern cites. Globe uses garish ...
(Date:4/25/2015)... York, New York (PRWEB) April 25, 2015 ... ) established for vaginal mesh lawsuits filed against ... the U.S. District Court, Southern District of West ... 9th, a Scheduling Conference was convened that day, ... Plaintiffs’ Master Long Form Complaint. The Order directed ...
Breaking Medicine News(10 mins):Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 2Health News:Brotherhood Mutual Insurance Company Selects Indiana Fiber Network, LLC for Fiber Transport Service 3Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 2Health News:North American Telugu Society Bestows Community Service Award to India Network Foundation for Its Generosity and Sponsor of Visitor Health Insurance to Indian Visitors 3Health News:The Connecticut Community for Addiction Recovery (CCAR) honors its volunteers during National Volunteer Recognition Week. 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 2Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 3Health News:C.R. Bard Vaginal Mesh Lawsuit News: Federal Litigation Issues New Pretrial Order Following Submission of Amended Responses to Master Complaint 4
... taken on time , , WEDNESDAY, May 7 (HealthDay News) -- ... miss doses when reminded by an electronic pillbox that both ... of pills to take and how to take them, new ... National Institute on Aging, was presented recently at the American ...
... SPOKANE, Wash., May 7 MIPSolutions, Inc. (OTC,Bulletin ... the,University of Utah has revealed a significant development ... that Molecularly Imprinted,Ionomer (MII) beads imprinted to retain ... This translates into decreased development,time, a large amount ...
... in Spanish and Chinese . ... translational research grant program will fund a pilot ... appropriate and improved diabetes care in rural communities ... Diabetes Self-Management Program (DSME), will help Filipinos with ...
... DaVita Inc. (NYSE:,DVA) announced that its Board ... current stock repurchase program. The increase, together ... $250,000,000 of,the Company,s common stock. The stock ... http://www.newscom.com/cgi-bin/prnh/20020729/DAVITALOGO ), Rich Whitney, CFO, ...
... May 7 Vaccinogen Inc. said Dutch health,authorities licensed ... clearing the path to more than $100 million of,potential ... facility based in Emmen, The,Netherlands also paves the way ... the final step before the vaccine can be sold ...
... Despite a weakened economy, a,challenging airline industry, and ... summer vacation plans, travel industry experts,observe; but they ... ), Jim Grace, President and CEO of ... "At InsureMyTrip.com, we are,seeing noticeable changes in the ...
Cached Medicine News:Health News:Electronic Pillbox Helps Seniors Stick to Drug Regimens 2Health News:Electronic Pillbox Helps Seniors Stick to Drug Regimens 3Health News:MIPSolutions, Inc. Reduces Expense and Development Time Associated With Precious Metal Extraction 2Health News:International Diabetes Federation gives grant to Philippine diabetes education program 2Health News:Dutch Authorize Manufacture of Vaccinogen's New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial 2Health News:InsureMyTrip.Com's Travel Insurance Tips for Protecting Your Summer Vacation 2Health News:InsureMyTrip.Com's Travel Insurance Tips for Protecting Your Summer Vacation 3
(Date:4/24/2015)... -- Hospira, Inc. (NYSE: HSP ), ... spoke about the importance of extrapolation in bringing biosimilars ... annual European Biosimilars Group conference in London ... publication of a pivotal white paper titled, "Why ... biosimilars." Speaking at the EGA conference, ...
(Date:4/23/2015)... , April 24, 2015  AbbVie (NYSE: ABBV ... Administration (FDA) has accepted its New Drug Application (NDA) ... two direct-acting antiviral treatment of ombitasvir, paritaprevir, ritonavir (OBV/PTV/r), ... of adults with chronic genotype 4 (GT4) hepatitis C ... first all-oral, interferon-free therapy being evaluated by the FDA ...
(Date:4/23/2015)... 23, 2015 Once again, BeaconMedaes is meeting ... to patient safety. BeaconMedaes, priority is to ... disease. The next generation Zone Valve Box ... are now mounted in the assembly, allowing for ease ... ceiling tiles potentially releasing dust spores and other bacteria ...
Breaking Medicine Technology:Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 2Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 3Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 4Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 5Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 6Hospira Leadership Presents at Preeminent European Biosimilars Forum, Announces New White Paper on Extrapolation 7U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 2U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 3U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 4U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 5U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 6U.S. FDA Grants Priority Review to AbbVie for Investigational, All-Oral, Interferon-Free Therapy for the Treatment of Genotype 4 Chronic Hepatitis C 7BeaconMedaes launches new Zone Valve Box Assembly 2
... The BIOM 3 (Binocular Indirect Ophthalmo-Microscope) incorporates ... microscope and enables a view of up to ... the BIOM 3 the eye may be rotated ... easily viewed. Even surgery through small pupils ...
... The Philips HeartStart Home Defibrillatorthe latest ... than 175,000 devices deployed, Philips is ... defibrillators on airplanes, and in airports, ... HeartStart Home Defibrillator is the first ...
... custom bars have a large body ... contacts (spaced 3 centimeters center-to-center) to ... repeated cleaning. Polarity indicators are molded ... handle fits our bar electrode styles. ...
... custom bars have a large body ... contacts (spaced 3 centimeters center-to-center) to ... repeated cleaning. Polarity indicators are molded ... handle fits our bar electrode styles. ...
Medicine Products: